Latest filing published 03 Sept 2026 for Tempus AI, Inc., €38k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jennifer A. Doudna discloses dealings in 2 companies, chiefly Tempus AI, Inc. and Scribe Therapeutics, Inc. In total, 19 filings cover trades dated from 13 June 2024 to 1 September 2026.
Sales make up the whole of the open-market record (16 sales, €1.1M). The rest of the record consists of 2 share grants. Since January 2026: no purchases and 3 sales on the market.
The newest entry dates from 3 September 2026: an open-market sale of €38k, in Tempus AI, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations